Karen Lingnau

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 85(Granted Patents)

Company Filing History:

Years Active: 2006-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11554169 - CMV vaccines (2023-01-17),

2. 10111945 - CMV vaccines (2018-10-30),

3. 9492537 - Methods and compositions involving immunostimulatory oligodeoxynucleotides (2016-11-15),

4. 9248180 - IC31 nanoparticles (2016-02-02),

5. 8945591 - Methods and compositions involving immunostimulatory oligodeoxynucleotides (2015-02-03),

6. 8784837 - Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule (2014-07-22),

7. 8765148 - 1C31 nanoparticles (2014-07-01),

8. 8568742 - Methods and compositions involving immunostimulatory oligodeoxynucleotides (2013-10-29),

9. 7858588 - Immunostimulatory oligodeoxynucleic molecules (2010-12-28),

10. 7704514 - Vaccines (2010-04-27),

11. 7244438 - Uses for polycationic compounds (2007-07-17),

12. 7148191 - Antigenic composition (2006-12-12),

Title: **Innovator Spotlight: Karen Lingnau**

Introduction

Karen Lingnau, a distinguished inventor based in Vienna, Austria, has made significant contributions to the field of medical science through her innovative inventions. With a remarkable portfolio of 12 patents, she has established herself as a vital player in the development of vaccines and therapeutic interventions.

Latest Patents

Among her latest innovations, Karen has focused on cytomegalovirus (CMV) vaccines. Her patents disclose genetically modified arenaviral vectors that are suitable for both the prevention and treatment of cytomegalovirus infections and reactivation. Furthermore, these patents encompass pharmaceutical compositions and comprehensive methods designed specifically for managing CMV infections. With this groundbreaking work, Karen is at the forefront of addressing significant health challenges associated with CMV.

Career Highlights

Throughout her career, Karen has worked with notable companies, such as Valneva Austria GmbH and Intercell AG. Her experiences in these organizations have provided her with valuable insights and opportunities to further her research and development efforts. Her pioneering work has not only contributed to scientific understanding but has also laid the groundwork for future advancements in vaccine technology.

Collaborations

Karen's collaborations have been instrumental in her success as an inventor. She has worked alongside esteemed colleagues, including Walter G Schmidt and Alena Egyed, whose expertise has complemented her own. Together, they have driven innovative projects forward, showcasing the importance of teamwork in the realm of scientific discovery.

Conclusion

Karen Lingnau's dedication to innovation and her impressive array of patents underscore her role as a leading figure in the medical field. Her work in developing CMV vaccines is a testimony to her commitment to improving public health outcomes. As she continues to push the boundaries of science, Karen’s contributions are sure to inspire future generations of inventors.

This text is generated by artificial intelligence and may not be accurate.